Therefore to our knowledge, our study is the first to discover that the TGFBR1/TAK1 pathway-mediated HASMC inflammation is involved in the pathological process of vascular calcification; the inhibition of this inflammation could serve as a new therapeutic target for retarding vascular calcification. This evidence concerns the gene TGFBR1 and calcification.